Search results
Najważniejsze informacje. • U dorosłych hospitalizowanych z powodu COVID-19, stosowanie remdesiwiru, w porównaniu z placebo (leczeniem pozorowanym) lub standardową opieką, ma prawdopodobnie niewielki lub żaden wpływ na ryzyko zgonu w ciągu 150 dni od rozpoczęcia leczenia.
- English
We differentiated between non-hospitalised individuals with...
- Bahasa Malaysia
Kami mencari kajian yang menyiasat remdesivir untuk merawat...
- Deutsch
In keiner Studie wurden Personen mit symptomloser...
- Remdesivir
中度至重度 covid-19 的住院患者. 瑞德西韋可能對 28 天、60 天後的死亡或 150...
- English
21 lut 2023 · This individual patient data meta-analysis showed that remdesivir reduced mortality in patients hospitalised with COVID-19 who required no or conventional oxygen support, but was underpowered to evaluate patients who were ventilated when receiving remdesivir.
21 maj 2022 · By contrast to their interim study that showed no decrease in mortality for patients receiving remdesivir, 1 the new Article reports both a decrease in mortality among non-ventilated adults with oxygen therapy (remdesivir 14·6% vs control 16·3%; RR 0·87 [95% CI 0·76–0·99], p=0·04) and a lower progression to mechanical ventilation or ...
5 paź 2020 · Remdesivir - podawany dożylnie w kroplówce - jest inhibitorem dla jednego z enzymów różnego typów koronawirusów, w tym wirusa SARS-CoV-2, a także Eboli. Zakłóca produkcję materiału genetycznego i...
Despite conditional recommendation against its use, remdesivir could still be effective in early clinical improvement; reduction of early mortality and avoiding high-flow supplemental oxygen and invasive mechanical ventilation among hospitalised COVID-19 patients.
30 lip 2020 · Remdesivir probably has no important effect on need for invasive mechanical ventilation. Remdesivir may have little or no effect on hospital length of stay. Understanding the recommendation: Most patients with severe covid-19 would likely choose treatment with remdesivir given the potential reduction in time to clinical improvement. However ...
30 lip 2020 · Remdesivir may increase the risk of serious adverse events leading to drug discontinuation (network meta-analysis odds ratio 1.26 (0.52 to 3.94), absolute effect estimate 1.9% more (3.7% fewer to 17.5% more), low certainty).
